Industry Responds to the UK Gov’s Levelling Up White Paper
ABPI has responded to the publication of a white paper on ‘Levelling Up’ by the government of the United Kingdom.
The Association of the British Pharmaceutical Industry (ABPI) has responded to the publication of a white paper on ‘Levelling Up’ by the government of the United Kingdom, in a statement released on Feb. 2, 2022.
The aim of the Levelling Up white paper is to provide details on how the government plans to spread out opportunity more equally within the UK by the year 2030. According to Richard Torbett, chief executive of the ABPI, it is essential that the country’s life sciences’ sector is strong to aid with levelling up.
“The sector is already represented in every region across the UK, but by backing life sciences—and through the creation of highly-skilled, well-paid jobs in science, R&D and manufacturing—there is even greater potential for the life sciences to help level up the UK,” Torbett said in the press release. “The commitment to close the healthy life expectancy gap by 2030 is particularly important. To close this gap and transform the lives of patients, we need to make sure that people can access the best possible care wherever they live in the UK. Getting this right must be central to the missions set out today.”
Source: ABPI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
